Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like...

Full description

Bibliographic Details
Authors: Ficarra, Guido, Prat Aparicio, Aleix, Conte, Pierfranco, Guarneri, Valentina, Griguolo, Gaia, Dieci, Maria Vittoria, Paré, Laia, Miglietta, Federica, Generali, Daniele, Frassoldati, Antonio, Cavanna, Luigi, Bisagni, Giancarlo, Piacentini, Federico, Tagliafico, Enrico, Cagossi, Katia
Format: article
Status:Published version
Publication Date:2021
Country:España
Institution:Universidad de Barcelona
Repository:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/226145
Online Access:https://hdl.handle.net/2445/226145
Access Level:Open access
Keyword:Càncer de mama
Receptors d'hormones
Antígens tumorals
Breast cancer
Hormone receptors
Tumor antigens
Description
Summary:Little is known regarding the interaction between immune microenvironment and tumorbiology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatmentgene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocytelevels than luminal tumors. Moreover, significant differences in immune infiltrate composition,assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatoryantitumor immune infiltrate composition than luminal ones.

Similar Items